High-risk groups (e.g. medical personnel, personnel who are frequently exposed to blood, staff of childcare institutions, organ transplant patients, frequent recipients of blood transfusions or blood products, immunocompromised persons, family members of HBsAg-positive persons, men who have sex with men, persons with multiple sexual partners and persons who inject drugs intravenously, etc.) should be treated as follows when there is accidental exposure of broken skin or mucous membranes to blood and body fluids of HBV-infected persons Treatment, to achieve the purpose of preventing hepatitis B virus infection. First, serological testing: HBV DNA, HBsAg, anti-HBs, HBeAg, anti-HBc, alanine aminotransferase (ALLT) and aspartate aminotransferase (AST) should be tested immediately and retested in 3 and 6 months. Second, immediate active and passive immunization: If you have received hepatitis B vaccine and are known to be anti-HBs positive, you may not be given special treatment. If you have not received hepatitis B vaccine, or if you have received hepatitis B vaccine but anti-HBs <10 IU/L or anti-HBs level is unknown, you should immediately administer HBIG 200-400 IU and receive 1 dose of hepatitis B vaccine (20 μg) at different sites at the same time, and receive the second and third doses of hepatitis B vaccine (20 μg each) 1 month and 6 months later, respectively.